Page 2047 - Williams Hematology ( PDFDrive )

2022 Part XII: Hemostasis and Thrombosis Chapter 117: Thrombocytopenia 2023

256. Alarcon-Segovia D, Deleze M, Oria CV, et al: Antiphospholipid antibodies and the anti- 289. Mok CC, Lee KW, Ho CT, et al: A prospective study of survival and prognostic indica-
phospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 tors of systemic lupus erythematosus in a southern Chinese population. Rheumatology
consecutive patients. Medicine (Baltimore) 68:353–365, 1989. (Oxford) 39:399–406, 2000.
257. Galli M, Finazzi G, Barbui T: Thrombocytopenia in the antiphospholipid syndrome. Br 290. Drenkard C, Villa AR, Alarcon-Segovia D, Perez-Vazquez ME: Influence of the anti-
J Haematol 93:1–5, 1996. phospholipid syndrome in the survival of patients with systemic lupus erythematosus.
258. Cuadrado MJ, Mujic F, Munoz E, et al: Thrombocytopenia in the antiphospholipid syn- J Rheumatol 21:1067–1072, 1994.
drome. Ann Rheum Dis 56:194–196, 1997. 291. Reveille JD, Bartolucci A, Alarcon GS: Prognosis in systemic lupus erythematosus.
259. Uthman I, Godeau B, Taher A, Khamashta M: The hematologic manifestations of the Negative impact of increasing age at onset, black race, and thrombocytopenia, as well
antiphospholipid syndrome. Blood Rev 22:187–194, 2008. as causes of death. Arthritis Rheum 33:37–48, 1990.
260. Harris EN: Antiphospholipid antibodies. Br J Haematol 74:1–9, 1990. 292. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J: Mortality studies in systemic
261. Wilson WA, Gharavi AE, Koike T, et al: International consensus statement on prelimi- lupus erythematosus. Results from a single center. II. Predictor variables for mortality.
nary classification criteria for definite antiphospholipid syndrome: Report of an inter- J Rheumatol 22:1265–1270, 1995.
national workshop. Arthritis Rheum 42:1309–1311, 1999. 293. Scofield RH, Bruner GR, Kelly JA, et al: Thrombocytopenia identifies a severe familial
262. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, et al: Antiphospholipid antibodies and phenotype of systemic lupus erythematosus and reveals genetic linkages at 1q22 and
antiphospholipid syndrome in patients presenting with immune thrombocytopenic 11p13. Blood 101:992–997, 2003.
purpura: A prospective cohort study. Blood 98:1760–1764, 2001. 294. Boumpas DT, Austin HA, III, Fessler BJ, et al: Systemic lupus erythematosus: Emerging
263. Galli M, Daldossi M, Barbui T: Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic
patients with antiphospholipid antibodies. Thromb Haemost 71:571–575, 1994. disease. Ann Intern Med 122:940–950, 1995.
264. Lipp E, von Felten A, Sax H, et al: Antibodies against platelet glycoproteins and anti- 295. Arnal C, Piette JC, Leone J, et al: Treatment of severe immune thrombocytopenia asso-
phospholipid antibodies in autoimmune thrombocytopenia. Eur J Haematol 60: ciated with systemic lupus erythematosus: 59 cases. J Rheumatol 29:75–83, 2002.
283–288, 1998. 296. Boumpas DT, Barez S, Klippel JH, Balow JE: Intermittent cyclophosphamide for the
265. Stasi R, Stipa E, Masi M, et al: Prevalence and clinical significance of elevated anti- treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann
phospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood Intern Med 112:674–677, 1990.
84:4203–4208, 1994. 297. Roach BA, Hutchinson GJ: Treatment of refractory, systemic lupus erythematosus-
266. Fabris F, Steffan A, Cordiano I, et al: Specific antiplatelet autoantibodies in patients with associated thrombocytopenia with intermittent low-dose intravenous cyclophosphamide.
antiphospholipid antibodies and thrombocytopenia. Eur J Haematol 53:232–236, 1994. Arthritis Rheum 36:682–684, 1993.
267. Nakamura M, Tanaka Y, Satoh T, et al: Autoantibody to CD40 ligand in systemic 298. Maier WP, Gordon DS, Howard RF, et al: Intravenous immunoglobulin therapy in
lupus erythematosus: Association with thrombocytopenia but not thromboembolism. systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum 33:
Rheumatology (Oxford) 45:150–156, 2006. 1233–1239, 1990.
268. Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and sec- 299. Cohen MG, Li EK: Limited effects of intravenous IgG in treating systemic lupus eryth-
ondary to SLE): First report from the Italian Registry. Italian Registry of Antiphospho- ematosus-associated thrombocytopenia. Arthritis Rheum 34:787–788, 1991.
lipid Antibodies (IR-APA). Haematologica 78:313–318, 1993. 300. Ding C, Foote S, Jones G: B-cell-targeted therapy for systemic lupus erythematosus: An
269. Bernini JC, Buchanan GR, Ashcraft J: Hypoprothrombinemia and severe hemorrhage update. BioDrugs 22:239–249, 2008.
associated with a lupus anticoagulant. J Pediatr 123:937–939, 1993. 301. Jovancevic B, Lindholm C, Pullerits R: Anti-B cell therapy against refractory thrombo-
270. Font J, Jimenez S, Cervera R, et al: Splenectomy for refractory Evans’ syndrome asso- cytopenia in SLE and MCTD patients: Long-term follow up and review of the literature.
ciated with antiphospholipid antibodies: Report of two cases. Ann Rheum Dis 59:920– Lupus 22:664–674, 2013.
923, 2000. 302. Zhou J, Wu Z, Zhou Z, et al: Efficacy and safety of laparoscopic splenectomy in thrombo-
271. Hakim AJ, Machin SJ, Isenberg DA: Autoimmune thrombocytopenia in primary anti- cytopenia secondary to systemic lupus erythematosus. Clin Rheumatol 32:1131–1138, 2013.
phospholipid syndrome and systemic lupus erythematosus: The response to splenec- 303. Delgado AJ, Inanc M, Diz-Kucukkaya R, et al: Thrombocytopenic risk in patients
tomy. Semin Arthritis Rheum 28:20–25, 1998. submitted to splenectomy for systemic lupus erythematosus and antiphospholipid syn-
272. Ames PR, Tommasino C, Fossati G, et al: Limited effect of rituximab on thrombo- drome-related thrombocytopenia. Eur J Intern Med 15:162–167, 2004.
cytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid 304. Ciernik IF, Cone RW, Fehr J, Weber R: Impaired liver function and retroviral activity
syndrome. Ann Hematol 86:227–228, 2007. are risk factors contributing to HIV-associated thrombocytopenia. Swiss HIV Cohort
273. Ahn ER, Lander G, Bidot CJ, et al: Long-term remission from life-threatening hyper- Study. AIDS 13:1913–1920, 1999.
coagulable state associated with lupus anticoagulant (LA) following rituximab therapy. 305. Dominguez A, Gamallo G, Garcia R, et al: Pathophysiology of HIV related thrombocy-
Am J Hematol 78:127–129, 2005. topenia: An analysis of 41 patients. J Clin Pathol 47:999–1003, 1994.
274. Kumar D, Roubey RA: Use of rituximab in the antiphospholipid syndrome. Curr Rheu- 306. Louache F, Vainchenker W: Thrombocytopenia in HIV infection. Curr Opin Hematol
matol Rep 12:40–44, 2010. 1:369–372, 1994.
275. Sperati CL, Streiff MB: Acute renal failure in a patient with antiphospholipid syndrome 307. Brook MG, Ayles H, Harrison C, et al: Diagnostic utility of bone marrow sampling in
and immune thrombocytopenic purpura treated with eltrombopag. Am J Hematol HIV positive patients. Genitourin Med 73:117–121, 1997.
85:724–726, 2010. 308. WHO Global Alert and Response. 2015. http://www.who.int/csr/disease/hepatitis/
276. Jansen AJ, Swart RM, te Boekhorst PA. Thrombopoietin receptor agonists for immune whocdscsrlyo2003/en/index1.html
thrombocytopenia. N Engl J Med 365:2240–2241, 2011. 309. Stasi R: Therapeutic strategies for hepatitis- and other infection-related immune
277. Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of thrombocytopenias. Semin Hematol 46:S15–S25, 2001.
systemic lupus erythematosus. Arthritis Rheum 25:1271–1277, 1982. 310. Calvaruso V, Craxi A: Immunological alterations in hepatitis C virus infection. World J
278. Hochberg MC: Updating the American College of Rheumatology revised criteria for Gastroenterol 19:8916–8923, 2013.
the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725, 1997. 311. Hamaia S, Allain JP: The dynamics of hepatitis C virus binding to platelets and 2 mono-
279. Rabinowitz Y, Dameshek W: Systemic lupus erythematosus after “idiopathic” thrombo- nuclear cell lines. Blood 98:2293–2300, 2001.
cytopenic purpura: A review. Ann Intern Med 52:1–28, 1960. 312. Cuker A: Toxicities of the thrombopoietic growth factors. Semin Hematol 47:289–298,
280. Michel M, Lee K, Piette JC, et al: Platelet autoantibodies and lupus-associated thrombo- 2010.
cytopenia. Br J Haematol 119:354–358, 2002. 313. Jackson S, Beck PL, Pineo GF, Poon MC: Helicobacter pylori eradication: Novel ther-
281. Pujol M, Ribera A, Vilardell M, et al: High prevalence of platelet autoantibodies in apy for immune thrombocytopenic purpura? A review of the literature. Am J Hematol
patients with systemic lupus erythematosus. Br J Haematol 89:137–141, 1995. 78:142–150, 2005.
282. McMillan R: Immune thrombocytopenia. Clin Haematol 12:69–88, 1983. 314. Franchini M, Cruciani M, Mengoli C, et al: Effect of Helicobacter pylori eradication
283. Macchi L, Rispal P, Clofent-Sanchez G, et al: Anti-platelet antibodies in patients with on platelet count in idiopathic thrombocytopenic purpura: A systematic review and
systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: meta-analysis. J Antimicrob Chemother 60:237–246, 2007.
Their relationship with the observed thrombocytopenia. Br J Haematol 98:336–341, 315. Arnold DM, Bernotas A, Nazi I, et al: Platelet count response to H. pylori treatment in
1997. patients with immune thrombocytopenic purpura with and without H. pylori infection:
284. Griner PF, Hoyer LW: Amegakaryocytic thrombocytopenia in systemic lupus erythe- A systematic review. Haematologica 94:850–856, 2009.
matosus. Arch Intern Med 125:328–332, 1970. 316. Burrows RF, Kelton JG: Incidentally detected thrombocytopenia in healthy mothers
285. Fureder W, Firbas U, Nichol JL, et al: Serum thrombopoietin levels and anti-thrombo- and their infants. N Engl J Med 319:142–145, 1988.
poietin antibodies in systemic lupus erythematosus. Lupus 11:221–226, 2002. 317. Letsky EA, Greaves M: Guidelines on the investigation and management of throm-
286. Kuwana M, Okazaki Y, Kajihara M, et al: Autoantibody to c-Mpl (thrombopoietin bocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. Maternal and
receptor) in systemic lupus erythematosus: Relationship to thrombocytopenia with Neonatal Haemostasis Working Party of the Haemostasis and Thrombosis Task Force
megakaryocytic hypoplasia. Arthritis Rheum 46:2148–2159, 2002. of the British Society for Haematology. Br J Haematol 95:21–26, 1996.
287. Feinglass EJ, Arnett FC, Dorsch CA, et al: Neuropsychiatric manifestations of systemic 318. Gernsheimer T, James AH, Stasi R: How I treat thrombocytopenia in pregnancy. Blood
lupus erythematosus: Diagnosis, clinical spectrum, and relationship to other features of 121:38–47, 2013.
the disease. Medicine (Baltimore) 55:323–339, 1976. 319. George JN, Saucerman S: Platelet IgG, IgA, IgM, and albumin: Correlation of platelet
288. Miller MH, Urowitz MB, Gladman DD: The significance of thrombocytopenia in sys- and plasma concentrations in normal subjects and in patients with ITP or dysproteine-
temic lupus erythematosus. Arthritis Rheum 26:1181–1186, 1983. mia. Blood 72:362–365, 1988.

Kaushansky_chapter 117_p1993-2024.indd 2022 9/21/15 2:34 PM